GSK licenses cancer immunotherapy from Surface Oncology

By The Science Advisory Board staff writers

December 17, 2020 -- GlaxoSmithKline (GSK) has obtained an exclusive license worldwide and commercial rights to Surface Oncology's preclinical program, SRF813, an antitumor antibody.

SRF813 is a fully human immunoglobulin G (IgG1) antibody targeting poliovirus receptor-related immunoglobulin domain-containing (PVRIG), an inhibitory protein expressed on natural killer (NK) cells and T cells. SRF813 binds to a distinct epitope on PVRIG and blocks the interaction of the protein with CD112, which is overexpressed in tumor cells.

In preclinical studies, the candidate promotes activation of both NK cells and T cells and has the potential to elicit strong antitumor responses and immunological memory. SRF813 is currently being evaluated in studies to support an investigational new drug (IND) application with an IND submission planned for 2021.

Under the agreement, GSK will make an $85 million upfront payment to Surface Oncology. In addition, Surface Oncology may receive up to an additional $730 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales.

Ideaya and GSK partner on synthetic lethality programs
Ideaya Biosciences and GlaxoSmithKline (GSK) have formed a strategic partnership in the emerging oncology field of synthetic lethality.

Copyright © 2020

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter